Regulatory BCL2 promoter polymorphism (-938C>A) is associated with adverse outcome in patients with prostate carcinoma.
Bachmann HS, Heukamp LC, Schmitz KJ, Hilburn CF, Kahl P, Buettner R, Nückel H, Eisenhardt A, Rübben H, Schmid KW, Siffert W, Eggert A, Schramm A, Schulte JH.
Bachmann HS, et al. Among authors: schmid kw.
Int J Cancer. 2011 Nov 15;129(10):2390-9. doi: 10.1002/ijc.25904. Epub 2011 Mar 25.
Int J Cancer. 2011.
PMID: 21207420